Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–7. https://doi.org/10.1016/j.urology.2010.08.039.

Article  PubMed  Google Scholar 

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49. https://doi.org/10.1016/S0090-4295(02)02243-4.

Article  PubMed  Google Scholar 

Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–63. https://doi.org/10.1016/j.juro.2012.09.079.

Article  PubMed  Google Scholar 

Raju R, Linder BJ. Evaluation and treatment of overactive bladder in women. Mayo Clin Proc. 2020;95(2):370–7. https://doi.org/10.1016/j.mayocp.2019.11.024.

Article  PubMed  Google Scholar 

Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. Urology. 2010;75(3):491–500. https://doi.org/10.1016/j.urology.2009.07.1325.

Article  PubMed  Google Scholar 

Enemchukwu EA, Subak LL, Markland A. Barriers and facilitators to overactive bladder therapy adherence. Neurourol Urodyn. 2022;41(8):1983–92. https://doi.org/10.1002/nau.24936.

Article  CAS  PubMed  Google Scholar 

Johnston KM, Walker DR, Lakzadeh P. Characterizing the health-related quality of life burden of overactive bladder using disease-specific patient-reported outcome measures: a systematic literature review. Adv Ther. 2019;36(3):548–62. https://doi.org/10.1007/s12325-019-0880-8.

Article  PubMed  PubMed Central  Google Scholar 

Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: Importance for determining clinical effectiveness of treatment. Urology. 2006;68(2 Supplement):3–8. https://doi.org/10.1016/j.urology.2006.05.045.

Article  Google Scholar 

Kim SK, Kim SH. The impact of overactive bladder on health-related quality of life in Korea: based on the results of a Korean Community Health Survey. Qual Life Res. 2021;30(4):1017–24. https://doi.org/10.1007/s11136-020-02710-3.

Article  PubMed  Google Scholar 

Kontogiannis S, Athanasopoulos A, Tsagkarakis M, Kontodimopoulos N. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder. Int Urogynecol J. 2022;33(11):3035–43. https://doi.org/10.1007/s00192-021-04991-9.

Article  PubMed  Google Scholar 

Gomes CM, Averbeck MA, Koyama M, Soler R. Impact of OAB symptoms on work, quality of life and treatment-seeking behavior in Brazil. Curr Med Res Opin. 2020;36(8):1403–15. https://doi.org/10.1080/03007995.2020.1760806.

Article  Google Scholar 

Santander J, Plata M, Zuluaga L, Azuero J, Daza F, Trujillo CG, et al. What is the real burden of the overactive bladder? Results from a national prevalence study. Neurourol Urodyn. 2022;41(4):926–34. https://doi.org/10.1002/nau.24894.

Article  Google Scholar 

• Lin XD, Lin N, Ke ZB, Xu N, Jiang P, Li H. Effects of overactive bladder syndrome on female sexual function. Medicine (Baltimore). 2021;100(20):e25761. https://doi.org/10.1097/md.0000000000025761. Case-control study examining the effect of OAB on female sexual function.

Article  CAS  Google Scholar 

Snedecor SJ. Review of economic value drivers of the treatment of overactive bladder. Pharmacoeconomics. 2018;36(9):1083–92. https://doi.org/10.1007/s40273-018-0663-0.

Article  PubMed  Google Scholar 

Iyer S, Amegashie C, deMartelly V, Letko J, Glass D, Fetzer L, et al. Patient perceptions impact progression to third-line therapy for treatment of overactive bladder. J Urol. 2021;206(5):1240–7. https://doi.org/10.1097/ju.0000000000001950.

Article  Google Scholar 

•• Tellechea L, Zuo S, Kohn JR, Fazzari MJ, Eisenberg R, Lee J, et al. The effect of social determinants of health on overactive bladder symptom severity. J Urol. 2021;205(5):1415–20. https://doi.org/10.1097/ju.0000000000001545. Cross-sectional study demonstrating higher OAB symptom scores are associated with food insecurity, financial strain, difficulty finding or keeping employment, and difficulty concentrating after adjusting for age, race, and BMI.

Kosilov K, Loparev S, Kuzina I, Kosilova L, Prokofyeva A. Socioeconomic status and health-related quality of life among adults and older with overactive bladder. Int J Qual Health Care. 2019;31(4):289–97. https://doi.org/10.1093/intqhc/mzy163.

Article  PubMed  Google Scholar 

Roselli N, McKay E, Nauheim J, Halani PK, Abraham NE. Health disparities and access to advanced therapy for overactive bladder. Neurourol Urodyn. 2022;41(8):1940–7. https://doi.org/10.1002/nau.24949.

Article  PubMed  Google Scholar 

Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41(8):1928–33. https://doi.org/10.1002/nau.25037.

Article  CAS  PubMed  Google Scholar 

Athavale A, Gooch K, Walker D, Suh M, Scaife J, Haber A, et al. A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US. Patient Prefer Adherence. 2018;12:2139–52. https://doi.org/10.2147/ppa.s178668.

Article  PubMed  PubMed Central  Google Scholar 

• Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, et al. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). Health Qual Life Outcomes. 2018;16(1):69. https://doi.org/10.1186/s12955-018-0892-0. Phase IV double-blind crossover study that compared mirabegron and tolterodine ER in treatment-naïve adults with OAB and demonstrated similar improvements in OAB symptom scores.

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Schermer CR. Factors associated with improvements in patient-reported outcomes during mirabegron or antimuscarinic treatment of overactive bladder syndrome: a registry study (PERSPECTIVE). Adv Ther. 2019;36(8):1906–21. https://doi.org/10.1007/s12325-019-00994-7.

Article  PubMed  PubMed Central  Google Scholar 

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021;13(4):425–34. https://doi.org/10.1111/luts.12382.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316–24. https://doi.org/10.1097/ju.0000000000000807. Phase III placebo- and active-controlled trial demonstrating the efficacy and safety of vibegron for treatment of OAB.

Frankel J, Varano S, Staskin D, Shortino D, Jankowich R, Mudd PN Jr. Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study. Int J Clin Pract. 2021;75(5):e13937. https://doi.org/10.1111/ijcp.13937.

Article  Google Scholar 

Kinjo M, Masuda K, Nakamura Y, Miyakawa J, Tambo M, Fukuhara H. Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study. Urology. 2023;175:67–73. https://doi.org/10.1016/j.urology.2023.02.003.

Article  PubMed  Google Scholar 

Paudel R, Lane GI. Delivering patient-centered care through shared decision making in overactive bladder. Neurourol Urodyn. 2022;41(4):884–93. https://doi.org/10.1002/nau.24915.

Article  PubMed  PubMed Central  Google Scholar 

Speed J, Welk B, Comiter C, Elliott C. Determining patient preferences in the treatment of medication-refractory overactive bladder. Neurourol Urodyn. 2023;42(2):419–26. https://doi.org/10.1002/nau.25109.

Article  PubMed  Google Scholar 

••Huang J, Fan Y, Zhao K, Yang C, Zhao Z, Chen Y, et al. Comparative efficacy of neuromodulation technologies for overactive bladder in adults: a network meta-analysis of randomized controlled trials. Neuromodulation. 2022. https://doi.org/10.1016/j.neurom.2022.06.004. Meta-analysis of clinical trials investigating the efficacy and perceived improvement of third-line therapies demonstrated SNM was the most effective for HRQoL improvement, urinary episodes, and urinary frequency.

Sonmez R, Yildiz N, Alkan H. Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: a prospective randomised controlled trial. Ann Phys Rehabil Med. 2022;65(1):101486. https://doi.org/10.1016/j.rehab.2021.101486.

Article  PubMed  Google Scholar 

Kapur A, Harandi AA, Cohen T, Ruan H, Dabrowski C, Anderson R, et al. An analysis of factors that influence patient preference of third-line therapy for overactive bladder. Neurourol Urodyn. 2022;41(8):1906–13. https://doi.org/10.1002/nau.25046.

Article  CAS  PubMed  Google Scholar